JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Moderate to severe atopic dermatitis was significantly improved for adolescents and adults treated with abrocitinib vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 210 KB
Released: July 20, 2020


Provided by Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer, Inc.

Related Content

Video from Clinical Care Options (CCO) featuring expert insights into the whole-patient approach including treatment selection, common comorbidities, and coordination of care for patients with PsO/PsA.

April W. Armstrong, MD, MPH Philip Mease, MD, MACR Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: August 27, 2021 Expired: August 26, 2022

Dr Philip Mease discusses key studies from EULAR 2021 on axSpA and axPsA that will affect clinical practice, reported by Clinical Care Options (CCO)

Philip Mease, MD, MACR Released: August 10, 2021

From EULAR 2021 and Clinical Care Options (CCO), new data on MRI scoring of structural lesions in sacroiliac joints in axSpA

Released: August 3, 2021

From Clinical Care Options (CCO) and Dr. Robert Sidbury, expert commentary on new data in atopic dermatitis evaluation and management.

Robert Sidbury, MD, MPH Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.